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Conclusions: The new convective model is a marked 
improvement over the current HTPS. Explicit modelling of 
fluids is particularly important when the bladder or its direct 
surroundings are part of the treatment target area. 
 
PO-0728   
Postoperative hypofractionated-accelerated radiotherapy 
in prostate cancer: a phase I-II study (ISIDE-PP-2) 
S. Cammelli1, G. Macchia2, E. Farina1, S. Cilla3, C. DiGesù2, V. 
Frascino4, A. Cortesi1, F. Deodato2, V. Valentini4, G. Frezza5 
1Policlinico Universitario S. Orsola-Malpighi, Radiotherapy 
Department, Bologna, Italy 
2Fondazione "Giovanni Paolo II" Catholic University of Sacred 
Hearth, Radiation Oncology Unit, Campobasso, Italy  
3Fondazione "Giovanni Paolo II" Catholic University of Sacred 
Hearth, Medical Physics Unit, Campobasso, Italy  
4Catholic University of Sacred Hearth, Radiation Oncology 
Unit, Roma, Italy 
5Ospedale Bellaria, Radiotherapy Department, Bologna, Italy  
 
Purpose/Objective: The prognosis of patients with high risk 
prostate cancer (PCa) is improved by adjuvant radiotherapy 
(RT) after radical prostatectomy (RP), although the 5 year 
biochemical recurrence free survival (bRFS) does not exceed 
75-80%. Hypofractionated RT allows shorter treatment time 
and is theoretically associated with an improvement in the 
probability of cure in patients with PCa. However, 
hypofractionated RT may be associated with a higher 
incidence of long-term advers effects. To date, definitive 
indications on safety and efficacy of this fractionation are 
not available, especially in patients undergoing RP. 
Therefore, aim of this study was to evaluate safety and 
efficacy of postoperative hypofractionated RT with based on 
SIB-IMRT technique. 
Materials and Methods: Patients with high-risk resected PCa 
(R1, pT3, Gleason Score > 7) were enrolled in the study. The 
dose to the prostate was 62.5 Gy (2.5 Gy / fraction). In 
patients with dissection of < 7 lymph nodes and with a risk of 
nodal involvement > 15%, prophylactic irradiation of pelvic 
lymph nodes was performed. Furthermore, according to the 
NCCN risk categories, adjuvant hormone therapy (HT) was 
prescribed (intermediate risk: 6 months; high risk: 24 
months); bRFS (PSA> 0.2 ng/ml), local control, disease-free 
and overall survival were assessed using the Kaplan-Meier 
method. Survival curves were compared by log-rank test 
(univariate analysis) and Cox Proportional Hazard Method 
(multivariate analysis, considering as covariates: stage, 
pretreatment PSA, Gleason Score, RT treatment modalities, 
HT duration). Patients were classified according to the NCCN 
2014 risk categories. 
Results: A total of 127 patients were enrolled in the study 
(R1: 83.3%, pT3-4: 81.6%, Gleason score > 7: 38.9%). The 
results of the analysis are shown in the table.  
 
Conclusions: In a phase I-II study on postoperative 
hypofractionated-accelerated RT plus HT based on risk 
factors, an acceptable incidence of acute and long-term side 
effects and an improved bRFS compared to standard 
postoperative RT were recorded. 
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Purpose/Objective: Recent studies have expanded the 
concept that the systemic inflammatory response has an 
important role in the progression of several solid tumours. 
The neutrophil-to-lymphocyte ratio (NLR), an easily 
determinable marker of systemic inflammation, has been 
associated with clinical outcome in various cancer entities. In 
the present study, we validated the prognostic relevance of 
an elevated pre-treatment NLR in a cohort of European 
patients with non-metastatic prostate cancer treated with 3D 
conformal radiotherapy. 
Materials and Methods: Data from 415 consecutive non-
metastatic prostate cancer patients treated with 3D 
conformal radiotherapy at a single tertiary academic center 
from 1999-2007 were included in this retrospective study. 
Clinical disease-free survival (DFS), distant metastases-free 
survival (DMFS), and overall survival (OS) were assessed using 
the Kaplan-Meier method. To evaluate the prognostic 
relevance, univariate and multivariate Cox regression models 
were performed for each endpoint.  
Results: Based on previous studies, an NLR cut-off value of 5 
was applied to differentiate between a low (<5) and high (≥5) 
NLR.  
In univariate analysis, the elevated NLR was significantly 
associated with decreased clinical PFS (HR 1.87, 95% CI 1.05-
3.32, p=0.033) that remained significant in the multivariate 
analysis (HR 2.53, 95%CI 1.40-4.59, p=0.002). Additionally, 
